Related Experiment Video
Updated: Jun 13, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Beware of undetected hypoglycaemia
Penchala S Mittadodla1, Mohammad Ahmad
1drpench@hotmail.com
Emergency Medicine Journal : EMJ
|April 14, 2010
Summary
Hypoglycaemia in diabetic patients can alter consciousness. Capillary blood glucose tests may show normal readings despite severe low blood sugar, delaying critical treatment.
Area of Science:
- Emergency Medicine
- Clinical Chemistry
- Diabetology
Background:
- Altered consciousness in diabetic patients often stems from hypoglycaemia.
- Emergency departments frequently use capillary blood glucose (CBG) tests for rapid assessment.
- Prompt diagnosis and treatment of hypoglycaemia are crucial for patient outcomes.
Observation:
- A case report highlights limitations of standard CBG devices.
- Spurious "normal" glucose readings were observed in patients with genuine hypoglycaemia.
- This discrepancy was confirmed by arterial blood gas (ABG) and laboratory venous blood analyses.
Findings:
- Capillary blood glucose meters can yield falsely normal results in specific hypoglycaemic scenarios.
- Significant discrepancies exist between point-of-care capillary glucose and laboratory venous glucose measurements.
- This underestimation of hypoglycaemia poses a diagnostic challenge in emergency settings.
Implications:
- Clinicians must be aware of CBG device limitations in diabetic emergencies.
- Confirmation with laboratory-based glucose testing may be necessary when clinical suspicion is high.
- Improved diagnostic strategies are needed to prevent delayed treatment of severe hypoglycaemia.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...